Palatin

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Adamis
GSK
Sangamo BioSciences
Roche
Bluebird Bio
ProQR Therapeutics
Geron
Amarin
Palatin
EyeGate
Galactin
Omeros
Atossa Genetics
Flag link:
Palatin's Female Sexual Function Drug Succeeds, Offers Large Upside
Palatin's Female Sexual Function Drug Succeeds, Offers Large Upside
Seeking Alpha
Palatin
female sexual dysfunction
bremelanotide
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
cabozantinib
Cobimetinib
Exelixis
Medivation
Xtandi
Celldex Therapeutics
glemba
Palatin
bremelanotide
CRLX101
Cerulean Pharma
Anthera Pharmaceuticals
Flag link:
NJ biotech firm develops 'female Viagra' for women with low sexual desire
NJ biotech firm develops 'female Viagra' for women with low sexual desire
The Star Ledger, NJ
bremelanotide
Palatin
female sexual dysfunction
Flag link:
Targeting An Untapped Female Sexual Dysfunction Drug Market
Targeting An Untapped Female Sexual Dysfunction Drug Market
Seeking Alpha
female sexual dysfunction
Osphena
Shionogi
flibanserin
Sprout Pharmaceuticals
bremelanotide
Palatin
Femprox
Apricus Biosciences
Flag link:
Biotech Stock Mailbag: Amarin, MannKind, Palatin
Biotech Stock Mailbag: Amarin, MannKind, Palatin
The Street
Amarin
MannKind
Palatin
Flag link:
Palatin Investors Prepared For The Long Haul With Another FSD Drug
Palatin Investors Prepared For The Long Haul With Another FSD Drug
Seeking Alpha
Palatin
FSD
bremelanotide
Flag link:
AstraZeneca halts development of anti-obesity drug
AstraZeneca halts development of anti-obesity drug
Marketwatch
obesity
Palatin
AstraZeneca
AZD2820
Flag link:
Merck's $303 Million Ambryx Deal Great For Investors
Merck's $303 Million Ambryx Deal Great For Investors
Seeking Alpha
Merck
Ambryx
AstraZeneca
GSK
Novartis
Pfizer
Palatin
Flag link:
5 Dirt Cheap Biotech Stocks Poised to Triple
5 Dirt Cheap Biotech Stocks Poised to Triple
Seeking Alpha
Adventrx
Chelsea Therapeutics
Keryx
Palatin
Rexahn
Flag link:
Palatin cuts half its workforce, discovery R&D
Palatin cuts half its workforce, discovery R&D
Fierce Biotech
Palatin
layoffs
Flag link: